Dare Bioscience Executive Compensation Revealed
Ticker: DARE · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 1401914
Sentiment: neutral
Topics: executive-compensation, DEF-14A, equity-awards
TL;DR
Dare Bioscience dropped its exec comp details for 2024 - check out the equity awards!
AI Summary
Dare Bioscience, Inc. filed its DEF 14A on April 24, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to its principal executive officer (PEO) and non-principal executive officers (Non-PEO/NEO), with details on year-end values and changes in fair value for outstanding awards.
Why It Matters
This filing provides transparency into how Dare Bioscience compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the specifics of executive compensation can sometimes signal underlying company performance or strategic shifts.
Key Numbers
- 2024 — Fiscal Year (Period covered by the executive compensation details.)
- 2023 — Fiscal Year (Prior fiscal year for comparative compensation data.)
- 2022 — Fiscal Year (Prior fiscal year for comparative compensation data.)
Key Players & Entities
- Dare Bioscience, Inc. (company) — Filer of the DEF 14A
- 20250424 (date) — Filing date of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for compensation details
- Cerulean Pharma Inc. (company) — Former company name
- Tempo Pharmaceuticals Inc (company) — Former company name
FAQ
What was the total compensation for the Principal Executive Officer (PEO) in 2024?
The filing details equity awards granted to PEO members for the fiscal year 2024, including year-end fair value and changes in fair value, but does not explicitly state a single total dollar amount for the PEO in the provided snippet.
How many Non-PEO/NEO members received equity awards in 2024?
The filing indicates that Non-PEO/NEO members received equity awards in 2024, with data points for year-end fair value and changes in fair value, but the exact number of recipients is not specified in this excerpt.
What is the company's primary business sector?
Dare Bioscience, Inc. is in the Pharmaceutical Preparations sector, SIC code 2834.
When did the company change its name from Cerulean Pharma Inc.?
The company changed its name from Cerulean Pharma Inc. on July 14, 2009.
What is the filing date of this DEF 14A?
This DEF 14A filing was made on April 24, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 regarding Dare Bioscience, Inc. (DARE).